FDA Approves Novo Nordisk's Oral Wegovy for Adult Weight Loss

22 December 2025

Key highlights

FDA approved Wegovy pill, the first oral GLP-1 for weight loss.
OASIS 4 trial showed ~17% weight loss if patients stayed on treatment.
1.5 mg starting dose available in January for $149 per month.
Wegovy reduces cardiovascular risks in adults with obesity.

FDA Approval

The FDA has approved Novo Nordisk's Wegovy pill, marking it as the first oral GLP-1 medication for weight loss in adults. This approval introduces a new option for obesity treatment in the U.S.

Clinical Trial Results

In the OASIS 4 trial, Wegovy tablets demonstrated an average weight loss of approximately 17% for patients who remained on treatment. The weight loss was around 14% regardless of treatment adherence.

Availability and Pricing

The Wegovy pill will be available starting in early January, with a 1.5 mg starting dose priced at $149 per month, including savings offers. The pill is produced in the U.S., with a robust supply ready for distribution.

Cardiovascular Benefits

Wegovy is the only GLP-1 medication indicated for weight loss that also helps prevent major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, alongside diet and exercise.

Source: Novo Nordisk